Luye Pharma Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4,492	4,937	3,239	2,324	2,438
Short-Term Investments	1,000	62	1,272	1,247	387.86
Trading Asset Securities	2,004	1,504	1,596	1,974	2,684
Cash & Short-Term Investments	7,495	6,503	6,106	5,544	5,510
Cash Growth	15.25%	6.50%	10.14%	0.62%	1.92%
Accounts Receivable	3,259	2,780	2,355	1,784	1,765
Other Receivables	1,763	1,598	320.52	550.76	668.41
Receivables	5,022	4,378	2,675	2,334	2,434
Inventory	956.54	911.89	827.86	772.94	746.34
Prepaid Expenses	346.17	323.6	94.13	466.54	-
Restricted Cash	5.27	-	-	32	31.98
Other Current Assets	1,408	1,192	999.44	1,636	1,675
Total Current Assets	15,233	13,308	10,703	10,786	10,397
Property, Plant & Equipment	5,303	5,339	5,089	4,589	4,203
Long-Term Investments	3,596	2,492	1,968	1,114	582.2
Goodwill	1,075	1,012	1,042	1,003	985.41
Other Intangible Assets	5,467	5,464	4,805	4,448	4,080
Long-Term Deferred Tax Assets	73.78	163.58	144.59	113.95	133.11
Long-Term Deferred Charges	1,316	1,122	1,513	1,536	1,362
Other Long-Term Assets	761.05	710.96	226.1	658.43	839.37
Total Assets	32,825	29,612	25,491	24,250	22,582
Accounts Payable	1,153	689.3	767.19	559.94	570.89
Accrued Expenses	546.68	626.1	746.77	686.18	430.41
Short-Term Debt	5,432	5,118	4,568	4,723	4,740
Current Portion of Long-Term Debt	1,227	2,447	609.05	2,102	500.62
Current Portion of Leases	35.32	19.79	18.5	15.25	22.75
Current Income Taxes Payable	298.67	294.39	200.33	133.2	141.14
Current Unearned Revenue	110.75	188.26	156.55	72.83	70.99
Other Current Liabilities	1,132	1,386	1,071	1,195	853.54
Total Current Liabilities	9,936	10,769	8,138	9,487	7,330
Long-Term Debt	3,586	2,694	3,176	2,241	4,208
Long-Term Leases	34.69	42.17	52.15	23.24	19.21
Long-Term Unearned Revenue	280.22	130.56	172.22	384.44	209.39
Pension & Post-Retirement Benefits	4.56	5.34	4.1	2.02	6.79
Long-Term Deferred Tax Liabilities	0.49	36.48	47.26	56.03	57.87
Other Long-Term Liabilities	624.47	181.03	372.65	1,013	1,636
Total Liabilities	14,466	13,859	11,962	13,208	13,468
Common Stock	518.84	486.11	486.11	456.95	455.84
Additional Paid-In Capital	5,064	4,250	4,159	3,077	1,716
Retained Earnings	8,446	7,832	7,381	6,667	6,062
Treasury Stock	-	-	-	-279.56	-279.56
Comprehensive Income & Other	2,043	1,587	505.21	254.46	534.04
Total Common Equity	16,073	14,155	12,531	10,176	8,488
Minority Interest	2,287	1,599	997.31	865.77	625.78
Shareholders' Equity	18,359	15,754	13,528	11,042	9,114
Total Liabilities & Equity	32,825	29,612	25,491	24,250	22,582
Total Debt	10,315	10,321	8,424	9,105	9,491
Net Cash (Debt)	-2,820	-3,818	-2,318	-3,560	-3,980
Net Cash Per Share	-0.72	-1.01	-0.62	-1.02	-1.16
Filing Date Shares Outstanding	3,995	3,762	3,762	3,550	3,541
Total Common Shares Outstanding	3,995	3,762	3,762	3,550	3,541
Working Capital	5,297	2,539	2,565	1,299	3,066
Book Value Per Share	4.02	3.76	3.33	2.87	2.40
Tangible Book Value	9,530	7,678	6,684	4,724	3,423
Tangible Book Value Per Share	2.39	2.04	1.78	1.33	0.97
Buildings	2,770	2,613	2,013	1,707	1,602
Machinery	4,442	4,119	3,636	3,408	3,031
Construction In Progress	751.55	884.73	1,381	1,081	832.93
Leasehold Improvements	61.69	59.49	54.98	43.93	40.26